| Q49148465 | Absence of excess mortality in critically ill patients with nosocomial Escherichia coli bacteremia |
| Q35559502 | Acquired bloodstream infection in the intensive care unit: incidence and attributable mortality. |
| Q43449387 | Anidulafungin: a new therapeutic approach in antifungal therapy. Pharmacology of anidulafungin |
| Q24244555 | Antifungal agents for preventing fungal infections in non-neutropenic critically ill patients |
| Q24246969 | Antifungal agents for preventing fungal infections in non-neutropenic critically-ill patients |
| Q83399830 | Antimicrobial drug resistance in Taiwan |
| Q36633724 | Assessment of candidemia-attributable mortality in critically ill patients using propensity score matching analysis |
| Q36547585 | Assessment of the types of catheter infectivity caused by Candida species and their biofilm formation. First study in an intensive care unit in Algeria |
| Q36506378 | Attributable mortality of candidemia: a systematic review of matched cohort and case-control studies |
| Q36641985 | Bench-to-bedside review: Candida infections in the intensive care unit |
| Q92592097 | Candida Bloodstream Infection: Changing Pattern of Occurrence and Antifungal Susceptibility over 10 Years in a Tertiary Care Saudi Hospital |
| Q37624708 | Candida colonization and candiduria in critically ill patients in the intensive care unit |
| Q36670916 | Candida infections in the intensive care unit: epidemiology, risk factors and therapeutic strategies. |
| Q50763957 | Candidaemia in an Irish tertiary referral hospital: epidemiology and prognostic factors. |
| Q46971625 | Candidemia and candiduria in critically ill patients admitted to intensive care units in France: incidence, molecular diversity, management and outcome |
| Q46681094 | Candidemia in a Brazilian tertiary care hospital: incidence, frequency of different species, risk factors and antifungal susceptibility |
| Q47619707 | Candidemia in critically ill patients: difference of outcome between medical and surgical patients |
| Q24195090 | Central venous catheter (CVC) removal for adult patients with candidaemia |
| Q26471135 | Central venous catheter (CVC) removal for patients of all ages with candidaemia |
| Q31054881 | Characteristics and risk factors for 28-day mortality of hospital acquired fungemias in ICUs: data from the EUROBACT study |
| Q49100750 | Clinical and economic outcomes in critically ill patients with nosocomial catheter-related bloodstream infections |
| Q33807195 | Clinical characteristics and risk factors for nosocomial candidemia in medical intensive care units: experience in a single hospital in Korea for 6.6 years |
| Q49109687 | Colonization status and appropriate antibiotic therapy for nosocomial bacteremia caused by antibiotic-resistant gram-negative bacteria in an intensive care unit |
| Q38531765 | Current recommendations and importance of antifungal stewardship for the management of invasive candidiasis |
| Q51257593 | Detection of candidaemia in high risk patients: can yield of blood cultures be improved by blind subculture? |
| Q53898899 | Early detection of systemic infections. |
| Q34273626 | Epidemiology of Candida species infections in critically ill non-immunosuppressed patients |
| Q29616758 | Epidemiology of invasive candidiasis: a persistent public health problem |
| Q37624691 | Epidemiology, incidence and risk factors for invasive candidiasis in high-risk patients |
| Q73102394 | Estimating attributable mortality of candidemia: clinical judgement vs matched cohort studies |
| Q50976863 | Fungemia in a university hospital: an epidemiological approach. |
| Q58653693 | Hospital-Acquired Candidemia in HIV-Infected Patients. Incidence, Risk Factors and Predictors of Outcome |
| Q38798523 | Host and Environmental Factors Influencing Individual Human Cytokine Responses |
| Q80659480 | ICU-acquired infections and sepsis: more of a deadly duo |
| Q64239047 | Impact of empirical treatment with antifungal agents on survival of patients with candidemia |
| Q94464871 | Impact of host- and early treatment-related factors on mortality in ICU patients with candidemia: a bicentric retrospective observational study |
| Q36642052 | Impact of invasive fungal infection on outcomes of severe sepsis: a multicenter matched cohort study in critically ill surgical patients |
| Q39092143 | Incidence, characteristics and outcome of ICU-acquired candidemia in India |
| Q49117149 | Influence of matching for exposure time on estimates of attributable mortality caused by nosocomial bacteremia in critically ill patients |
| Q40883822 | Initial antifungal strategy does not correlate with mortality in patients with candidemia. |
| Q89395812 | Invasive Candida Infections in the ICU: Diagnosis and Therapy |
| Q49124894 | Invasive aspergillosis in critically ill patients: analysis of risk factors for acquisition and mortality |
| Q35010671 | Invasive candidiasis in non-hematological patients |
| Q44590119 | Invasive candidiasis in non-neutropenic adults : Guideline-based management in the intensive care unit |
| Q37514625 | Invasive candidiasis: an overview from Taiwan |
| Q46711915 | Invasive candidiasis: comparison of management choices by infectious disease and critical care specialists |
| Q44742489 | Invasive devices: no need? No use! |
| Q46683505 | Invasive fungal infections at The Norwegian Radium Hospital 1998-2003. |
| Q36540976 | Invasive fungal infections in critically ill patients: different therapeutic options and a uniform strategy |
| Q44020369 | Invasive fungal infections in the intensive care unit: a multicentre, prospective, observational study in Italy (2006-2008). |
| Q34280580 | Management of Candida species infections in critically ill patients |
| Q35904821 | Management of invasive candidiasis in critically ill patients |
| Q43082447 | Management of invasive candidiasis in the intensive care unit |
| Q37098160 | Multidisciplinary approach to the treatment of invasive fungal infections in adult patients. Prophylaxis, empirical, preemptive or targeted therapy, which is the best in the different hosts? |
| Q35587111 | New approaches to the risk of Candida in the intensive care unit |
| Q38589279 | Nosocomial Candidiasis: Antifungal Stewardship and the Importance of Rapid Diagnosis |
| Q35406737 | Novel strategies to fight Candida species infection. |
| Q38061190 | Occurrence, presentation and treatment of candidemia |
| Q38215111 | Our 2014 approach to candidaemia |
| Q37702237 | Pharmacoeconomics of voriconazole |
| Q38009066 | Practical considerations on current guidelines for the management of non-neutropenic adult patients with candidaemia |
| Q36128742 | Predicting invasive fungal disease due to Candida species in non-neutropenic, critically ill, adult patients in United Kingdom critical care units. |
| Q53887873 | Prospective evaluation of the epidemiology, microbiology, and outcome of bloodstream infections in adult surgical cancer patients. |
| Q49731842 | Ras signalling in pathogenic yeasts. |
| Q42363614 | Residual Attributable Mortality, a New Concept for Understanding the Value of Antibiotics in Treating Life-Threatening Acute Infections |
| Q45892642 | Resource utilization and cost of treatment with anidulafungin or fluconazole for candidaemia and other forms of invasive candidiasis: focus on critically ill patients |
| Q90436045 | Risk factors for candidemia: a prospective matched case-control study |
| Q39665961 | Species and susceptibility distribution of 1062 clinical yeast isolates to azoles, echinocandins, flucytosine and amphotericin B from a multi-centre study |
| Q36658546 | Temporal Trends of the Clinical, Resource Use and Outcome Attributes of ICU-Managed Candidemia Hospitalizations: A Population-Level Analysis |
| Q48555324 | The Lowbury Lecture. The United States approach to strategies in the battle against healthcare-associated infections, 2006: transitioning from benchmarking to zero tolerance and clinician accountability |
| Q34586566 | The epidemiology, antifungal use and risk factors of death in elderly patients with candidemia: a multicentre retrospective study |
| Q38612382 | The role of heparin in sepsis: much more than just an anticoagulant. |
| Q46600220 | Therapeutic efficacy of anidulafungin for the treatment of oesophageal candidiasis, candidemia and invasive candidiasis |
| Q35020546 | Time to blood culture positivity as a predictor of clinical outcome in patients with Candida albicans bloodstream infection |
| Q35959489 | Treatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin:review of the literature |
| Q37443139 | Treatment of candidemia and invasive candidiasis in the intensive care unit: post hoc analysis of a randomized, controlled trial comparing micafungin and liposomal amphotericin B. |
| Q43191432 | Update: invasive fungal infections: Diagnosis and treatment in surgical intensive care medicine |
| Q49105414 | Ventilator-associated pneumonia in a tertiary care ICU: analysis of risk factors for acquisition and mortality |
| Q48544823 | What Could Be the Role of Antifungal Lock-Solutions? From Bench to Bedside |
| Q47749829 | What has changed in the treatment of invasive candidiasis? A look at the past 10 years and ahead. |
| Q82735043 | [Candida peritonitis] |
| Q82653839 | [Epidemiology of candidemia in ICU] |
| Q82653825 | [Importance of invasive candidiasis in critical non-neutropenic patients] |
| Q45942586 | [Role of anidulafungin in critically ill patients]. |
| Q81434874 | [Therapeutic strategies in intensive care units] |